Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Pulmonology

Long-term Monitoring & Prognosis

At a Glance

Long-term monitoring of idiopathic bronchiectasis requires tracking disease severity with BSI or FACED scores and performing regular sputum cultures. Routine lung function tests and specialist check-ins help detect harmful bacteria early, adjust treatments, and preserve your lung health.

While idiopathic bronchiectasis is a lifelong journey, doctors use specific tools to track progress and ensure treatments are working. Monitoring is not just about reacting to flares; it is about gathering data to protect long-term health and maintain a high quality of life [1][2].

Measuring Severity: BSI and FACED Scores

To move away from guesswork, specialists use validated scoring systems to measure how “active” or severe the disease is. These scores help determine how aggressive the treatment plan needs to be [3][4].

  • Bronchiectasis Severity Index (BSI): This is a comprehensive tool that looks at age, BMI, lung function (FEV1), recent hospitalizations, and whether specific bacteria like Pseudomonas are present in the lungs. It is excellent at predicting the risk of future hospitalizations and severe flare-ups [4][5].
  • FACED Score: This is a simpler five-point scale focusing on lung function, age, Pseudomonas colonization, the number of lobes affected on the CT scan, and the level of shortness of breath. It is particularly helpful for predicting long-term lung health trends and disease progression [4][3].

The Role of Sputum Monitoring

Routine sputum cultures are a mandatory part of care, even during periods of stability [1]. Lungs can host bacteria that do not always cause immediate symptoms but can lead to long-term damage if left unchecked [6].

  • Pseudomonas aeruginosa: This is a particularly aggressive bacterium. If it takes up permanent residence (colonization) in the airways, it is associated with a higher risk of disease progression, more severe lung damage, and more frequent hospital visits [7][8]. Finding it early allows doctors to try an “eradication” protocol to clear it before it becomes permanent [9].
  • Nontuberculous Mycobacteria (NTM): These are slow-growing environmental bacteria that can cause progressive lung damage. Because they require very specific, long-term antibiotic combinations, early detection is vital [10][11].

The Psychological Impact

Living with a chronic condition and managing a heavy daily treatment burden (like 30–60 minutes of daily airway clearance) can take a significant toll on mental health [12][13].

  • Anxiety and Depression: It is very common for bronchiectasis patients to experience “scan anxiety” (fear of what a CT scan might show) or feelings of depression related to the permanence of the diagnosis [14][15].
  • Quality of Life (QOL) Tools: Doctors may use questionnaires like the QOL-B or the Bronchiectasis Health Questionnaire (BHQ). These are not just casual check-ins—they are scientific tools that help the medical team understand how the disease is affecting a patient’s energy, emotions, and social life [16][17].

A Monitoring Checklist

While every patient is different, a standard monitoring plan often includes:

  1. Sputum Cultures: Every 3–6 months, or at the start of any flare-up [1][2].
  2. Spirometry (Lung Function): At least once or twice a year to track how much air the lungs can move [2].
  3. Specialist Review: Seeing a pulmonologist who specializes in bronchiectasis at least once a year to update the BSI or FACED scores [2].
  4. Mental Health Screen: A regular discussion about mood and how well the treatment burden is being managed [18].

Common questions in this guide

What is the Bronchiectasis Severity Index (BSI)?
The Bronchiectasis Severity Index is a validated tool that uses your age, lung function, and sputum culture results to measure disease severity. It helps your pulmonologist predict the risk of future flare-ups and determine how aggressive your treatment plan needs to be.
Why do I need to give regular sputum samples if I feel fine?
Routine sputum cultures help detect harmful bacteria like Pseudomonas or NTM before they cause major flare-ups or long-term lung damage. Finding these bacteria early allows your medical team to try an eradication protocol to clear the infection before it becomes permanent.
What does the FACED score measure?
The FACED score is a straightforward scale that looks at lung function, age, bacteria colonization, CT scan results, and your level of shortness of breath. It is primarily used to predict long-term lung health trends and track disease progression over time.
How often should I see a pulmonologist for monitoring?
A standard monitoring plan generally involves seeing a pulmonologist who specializes in bronchiectasis at least once a year. During these visits, your doctor will update your severity scores, review spirometry results, and discuss how you are managing your daily treatments.
Is it normal to feel anxious or depressed about my bronchiectasis treatments?
Yes, managing a chronic lung condition and dedicating time to daily airway clearance can cause significant stress, anxiety, or depression. Doctors often use specialized questionnaires to understand how the disease and treatment burden are affecting your emotional well-being.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current Bronchiectasis Severity Index (BSI) or FACED score, and what does it tell us about my individual risk?
  2. 2.How frequently should I be providing sputum samples for culture, even if I feel relatively well?
  3. 3.What is the specific plan if we detect Pseudomonas aeruginosa or NTM in my sputum for the first time?
  4. 4.How often do I need to repeat my spirometry (lung function) tests or HRCT scans?
  5. 5.Are there mental health resources or support groups you recommend for patients dealing with the daily burden of chronic lung disease?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Non-CF bronchiectasis: Orphan disease no longer.

    Imam JS, Duarte AG

    Respiratory medicine 2020; (166()):105940 doi:10.1016/j.rmed.2020.105940.

    PMID: 32250872
  2. 2

    [Bronchiectasis - a review].

    Gudmundsson G, Juliusson G

    Laeknabladid 2020; (106(7)):352-361 doi:10.17992/lbl.2020.0708.592.

    PMID: 32608358
  3. 3

    Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis.

    He M, Zhu M, Wang C, et al.

    Bioscience reports 2020; (40(10)) doi:10.1042/BSR20194514.

    PMID: 33057706
  4. 4

    Assessment of the Non-Cystic Fibrosis Bronchiectasis Severity: The FACED Score vs the Bronchiectasis Severity Index.

    Minov J, Karadzinska-Bislimovska J, Vasilevska K, et al.

    The open respiratory medicine journal 2015; (9()):46-51 doi:10.2174/1874306401509010046.

    PMID: 25893025
  5. 5

    Association Between Non-Cystic Fibrosis Bronchiectasis and Quality of Life: A Single-Center Cross-Sectional Study.

    Chaurasia S, Haran A, Reddy A, Chawla P

    Cureus 2021; (13(3)):e14231 doi:10.7759/cureus.14231.

    PMID: 33959430
  6. 6

    Non-cystic fibrosis bronchiectasis in Taiwan.

    Chang CL, Sheu CC, Wang PH, et al.

    BMJ open respiratory research 2025; (12(1)) doi:10.1136/bmjresp-2024-003100.

    PMID: 41043967
  7. 7

    A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis.

    Finch S, McDonnell MJ, Abo-Leyah H, et al.

    Annals of the American Thoracic Society 2015; (12(11)):1602-11 doi:10.1513/AnnalsATS.201506-333OC.

    PMID: 26356317
  8. 8

    Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications.

    Kwok WC, Ho JCM, Tam TCC, et al.

    Respiratory research 2021; (22(1)):132 doi:10.1186/s12931-021-01729-5.

    PMID: 33910573
  9. 9

    Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis.

    Conceição M, Shteinberg M, Goeminne P, et al.

    European respiratory review : an official journal of the European Respiratory Society 2024; (33(171)) doi:10.1183/16000617.0178-2023.

    PMID: 38296344
  10. 10

    Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan.

    Lin CY, Huang HY, Hsieh MH, et al.

    Frontiers in microbiology 2022; (13()):868435 doi:10.3389/fmicb.2022.868435.

    PMID: 35509319
  11. 11

    New-onset nontuberculous mycobacterial pulmonary disease in bronchiectasis: tracking the clinical and radiographic changes.

    Kwak N, Lee JH, Kim HJ, et al.

    BMC pulmonary medicine 2020; (20(1)):293 doi:10.1186/s12890-020-01331-3.

    PMID: 33172424
  12. 12

    Factors related to depression and anxiety in adults with bronchiectasis.

    Özgün Niksarlioglu EY, Özkan G, Günlüoğlu G, et al.

    Neuropsychiatric disease and treatment 2016; (12()):3005-3010 doi:10.2147/NDT.S121147.

    PMID: 27920537
  13. 13

    Factors Associated With Quality of Life in Subjects With Stable COPD.

    Ekici A, Bulcun E, Karakoc T, et al.

    Respiratory care 2015; (60(11)):1585-91 doi:10.4187/respcare.03904.

    PMID: 26152471
  14. 14

    The prevalence and implications of depression and anxiety in patients with bronchiectasis: a systematic review and meta-analysis.

    Chang MS, Kim HJ, Lee JH

    ERJ open research 2024; (10(6)) doi:10.1183/23120541.00248-2024.

    PMID: 39655172
  15. 15

    The prevalence of anxiety and depression in bronchiectasis patients and their association with disease severity: a cross-sectional study.

    Al Oweidat K, Marie D, Toubasi AA, et al.

    Scientific reports 2023; (13(1)):20886 doi:10.1038/s41598-023-48276-1.

    PMID: 38017245
  16. 16

    The development and validation of the Bronchiectasis Health Questionnaire.

    Spinou A, Siegert RJ, Guan WJ, et al.

    The European respiratory journal 2017; (49(5)) doi:10.1183/13993003.01532-2016.

    PMID: 28495688
  17. 17

    A study of the psychometric properties of the Brazilian...Portuguese version of Bronchiectasis Health Questionnaire.

    Luppo A, de Camargo CO, Birring SS, et al.

    Pulmonology 2023; (29(1)):42-49 doi:10.1016/j.pulmoe.2020.10.012.

    PMID: 33386281
  18. 18

    The Predictive Role of Psychological Status and Disease Severity Indexes on Quality of Life Among Patients with Non-CF Bronchiectasis.

    Ceyhan B, Bekir M, Kocakaya D, et al.

    Turkish thoracic journal 2022; (23(1)):17-24 doi:10.5152/TurkThoracJ.2021.21142.

    PMID: 35110196

This page provides educational information on long-term monitoring for idiopathic bronchiectasis. Always consult your pulmonologist to interpret your specific severity scores and test results.

Get notified when new evidence is published on Idiopathic bronchiectasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.